Immunotherapy News and Research

Latest Immunotherapy News and Research

Johns Hopkins Medicine celebrates opening of Pavilion III at Green Spring Station

Johns Hopkins Medicine celebrates opening of Pavilion III at Green Spring Station

Intensive new combination therapy for ovarian cancer shows promising results

Intensive new combination therapy for ovarian cancer shows promising results

Novel immunotherapy combination could provide fresh hope for patients with cervical cancer

Novel immunotherapy combination could provide fresh hope for patients with cervical cancer

World's largest road hockey fundraiser raises $3.1 million to conquer cancer

World's largest road hockey fundraiser raises $3.1 million to conquer cancer

Combination of two immunotherapy drugs stops or reverses progression of advanced melanoma

Combination of two immunotherapy drugs stops or reverses progression of advanced melanoma

PARP inhibitor combined with chemotherapy increases survival for newly diagnosed ovarian cancer patients

PARP inhibitor combined with chemotherapy increases survival for newly diagnosed ovarian cancer patients

Rice chemist explores how extra amino acid could be used to make life-saving substances

Rice chemist explores how extra amino acid could be used to make life-saving substances

Cancer Research Institute declares 2019 recipients of top scientific and philanthropic awards

Cancer Research Institute declares 2019 recipients of top scientific and philanthropic awards

Children's of Alabama using cold sore virus to fight pediatric brain cancer

Children's of Alabama using cold sore virus to fight pediatric brain cancer

Adding radiation after immunotherapy increases PFS for some patients with metastatic NSCLC

Adding radiation after immunotherapy increases PFS for some patients with metastatic NSCLC

New NIH program aims to improve lives for people with inherited blood and immune diseases

New NIH program aims to improve lives for people with inherited blood and immune diseases

Tasmanian devil study may give clues to how cancers evade the immune system

Tasmanian devil study may give clues to how cancers evade the immune system

Metabolic imbalance in cancer patients associated with resistance to immune checkpoint blocker

Metabolic imbalance in cancer patients associated with resistance to immune checkpoint blocker

UCLA researchers identify new drug delivery pathway to stop tumor growth

UCLA researchers identify new drug delivery pathway to stop tumor growth

GlobalData: First peanut allergy therapy unlikely to be a good choice for all patients

GlobalData: First peanut allergy therapy unlikely to be a good choice for all patients

Oncologists respond quickly to emerging FDA safety data for drugs, study finds

Oncologists respond quickly to emerging FDA safety data for drugs, study finds

Wistar awarded more than $12 million to study opioid use in HIV-infected people

Wistar awarded more than $12 million to study opioid use in HIV-infected people

Wake Forest Baptist receives multimillion-dollar grant for innovative cancer care research

Wake Forest Baptist receives multimillion-dollar grant for innovative cancer care research

U-M and Karmanos receive NCI grant to find new solutions for prostate cancer

U-M and Karmanos receive NCI grant to find new solutions for prostate cancer

New clinical trial tests immunotherapy drug for prostate cancer patients on active surveillance

New clinical trial tests immunotherapy drug for prostate cancer patients on active surveillance

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.